Explore

Trendline Trendline
IDEAYA Biosciences Initiates Phase 1 Trial for IDE574, Targeting Multiple Solid Tumors

IDEAYA Biosciences Initiates Phase 1 Trial for IDE574, Targeting Multiple Solid Tumors

IDEAYA Biosciences Initiates Phase 1 Trial for IDE574, Targeting Multiple Solid Tumors
Rapid Read Rapid Read
St. Jude Researchers Enhance Immunotherapy by Restoring Mitochondrial Function in Dendritic Cells

St. Jude Researchers Enhance Immunotherapy by Restoring Mitochondrial Function in Dendritic Cells

Researchers at St. Jude Children’s Research Hospital have discovered a new metabolic mechanism that tumors use to disable dendritic cells, which are crucial for initiating an immune response against cancer. The study, published in Science, reveals that tumors impair dendritic cell function by reducing mitochondrial fitness, thereby weakening the immune system's ability to fight cancer. By enhancing mitochondrial function in these cells, the researchers were able to restore their activity and improve the efficacy of existing immunotherapies. In preclinical mouse models, introducing dendritic cells with high mitochondrial activity into tumors restored immunogenic activity and improved tumor control.
Trendline Trendline
ABION's Preclinical Data Shows ABN202 Outperforms TROP2-Targeting ADCs in Cancer Treatment

ABION's Preclinical Data Shows ABN202 Outperforms TROP2-Targeting ADCs in Cancer Treatment

ABION's Preclinical Data Shows ABN202 Outperforms TROP2-Targeting ADCs in Cancer Treatment
Rapid Read Rapid Read
American Cancer Society Launches New Journal for Pediatric and Young Adult Cancer Research

American Cancer Society Launches New Journal for Pediatric and Young Adult Cancer Research

The American Cancer Society (ACS) has announced the launch of a new medical journal, Pediatric, Adolescent & Young Adult Cancer, dedicated to advancing research in cancers affecting children, adolescents, and young adults. This open-access journal will feature peer-reviewed research and content on prevention, early detection, treatment, and survivorship in pediatric and AYA oncology. Dr. Nirali N. Shah, a physician-scientist at the National Cancer Institute, has been appointed as the inaugural editor-in-chief. The journal aims to provide a platform for researchers, clinicians, and advocates to share discoveries and advance knowledge in the field. It will cover novel treatment approaches, prevention strategies, and AI-driven insights, among other topics.
Trendline Trendline
Gilead Acquires Tubulis GmbH in $5 Billion Deal to Enhance Cancer Drug Pipeline

Gilead Acquires Tubulis GmbH in $5 Billion Deal to Enhance Cancer Drug Pipeline

Gilead Acquires Tubulis GmbH in $5 Billion Deal to Enhance Cancer Drug Pipeline
Rapid Read Rapid Read
Restoring Mitochondrial Function in Dendritic Cells Enhances Cancer Immunotherapy

Restoring Mitochondrial Function in Dendritic Cells Enhances Cancer Immunotherapy

Researchers at St. Jude Children's Research Hospital have discovered a new metabolic mechanism that could enhance cancer immunotherapy by restoring mitochondrial function in dendritic cells. The study, published in Science, reveals that tumors impair dendritic cell function by reducing mitochondrial activity, which weakens the immune response against cancer. By boosting mitochondrial function, researchers were able to enhance antitumor immune activity and improve the efficacy of existing immunotherapies. The study demonstrated that introducing dendritic cells with high mitochondrial activity into tumors in preclinical models restored immunogenic activity and improved tumor control.
Trendline Trendline
Gilead Sciences to Acquire Tubulis for $5 Billion, Enhancing Cancer Treatment Capabilities

Gilead Sciences to Acquire Tubulis for $5 Billion, Enhancing Cancer Treatment Capabilities

Gilead Sciences to Acquire Tubulis for $5 Billion, Enhancing Cancer Treatment Capabilities
Trendline Trendline
Vyome to Present Phase 2 Clinical Data on VT-1953 for MFW Treatment at AACR 2026

Vyome to Present Phase 2 Clinical Data on VT-1953 for MFW Treatment at AACR 2026

Vyome to Present Phase 2 Clinical Data on VT-1953 for MFW Treatment at AACR 2026
Trendline Trendline
Convergent Therapeutics CEO Discusses Radiopharmaceuticals in Oncology on BioSpace Podcast

Convergent Therapeutics CEO Discusses Radiopharmaceuticals in Oncology on BioSpace Podcast

Convergent Therapeutics CEO Discusses Radiopharmaceuticals in Oncology on BioSpace Podcast
Rapid Read Rapid Read
Canadian Researchers Identify New Glioblastoma Treatment Pathway Using Existing HIV Drug

Canadian Researchers Identify New Glioblastoma Treatment Pathway Using Existing HIV Drug

A team of researchers in Canada has discovered a new method to slow the growth of glioblastoma, a highly aggressive and currently incurable brain cancer. The study, conducted by scientists at McMaster University and The Hospital for Sick Children (SickKids), reveals that certain brain cells, previously thought to only support normal nerve function, can actually aid in the growth and spread of glioblastoma. These cells communicate with tumor cells, strengthening them. By blocking this communication in laboratory models, researchers observed a significant reduction in tumor growth. The study also highlights a potential treatment opportunity using an existing HIV drug, Maraviroc, which could interfere with this process. This discovery offers a new treatment option for patients who currently have limited choices, as glioblastoma often results in survival measured in months.
Trendline Trendline
Convergent Therapeutics Discusses Radiopharmaceuticals in Oncology on BioSpace Podcast

Convergent Therapeutics Discusses Radiopharmaceuticals in Oncology on BioSpace Podcast

Convergent Therapeutics Discusses Radiopharmaceuticals in Oncology on BioSpace Podcast
Rapid Read Rapid Read
Study Warns Vitamin B3 Supplements May Aid Cancer Cell Survival, Impacting Chemotherapy

Study Warns Vitamin B3 Supplements May Aid Cancer Cell Survival, Impacting Chemotherapy

A recent study from Case Western Reserve University’s School of Medicine, published in Cancer Letters, has raised concerns about the use of vitamin B3 supplements, specifically nicotinamide mononucleotide (NMN), nicotinamide riboside (NR), and nicotinamide (NAM), in cancer treatment. These supplements are popular for boosting energy and supporting healthy aging by increasing levels of NAD+, a molecule crucial for metabolism and cellular repair. However, the study suggests that these supplements may inadvertently aid pancreatic cancer cells in surviving chemotherapy. Pancreatic cancer, known for its low five-year survival rate of 13%, poses significant treatment challenges, and any factor that affects treatment efficacy is critical. The research indicates that NAD+ supplements can enhance cancer cell energy, reduce oxidative stress, and limit DNA damage, thereby making tumors more resistant to chemotherapy.